40576-21-4 Usage
Uses
Used in Medical and Dental Procedures:
PIPERIDINO(3-PIPERIDINYL)METHANONE HYDROCHLORIDE is used as a local anesthetic for medical and dental procedures to numb the area and reduce pain. Its application reason is its ability to block nerve signals, leading to a temporary loss of sensation and providing effective pain relief during surgeries, dental work, and other invasive procedures.
Used in Cardiology:
In the field of cardiology, PIPERIDINO(3-PIPERIDINYL)METHANONE HYDROCHLORIDE is used as an antiarrhythmic drug to manage abnormal heart rhythms. Its application reason is its capacity to stabilize the electrical activity of the heart, preventing the occurrence of arrhythmias and ensuring a regular heartbeat.
It is crucial to use PIPERIDINO(3-PIPERIDINYL)METHANONE HYDROCHLORIDE under the supervision of a healthcare professional to ensure its safe and effective use, as well as to avoid any potential side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 40576-21-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,0,5,7 and 6 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 40576-21:
(7*4)+(6*0)+(5*5)+(4*7)+(3*6)+(2*2)+(1*1)=104
104 % 10 = 4
So 40576-21-4 is a valid CAS Registry Number.
InChI:InChI=1/C11H20N2O.ClH/c14-11(10-5-4-6-12-9-10)13-7-2-1-3-8-13;/h10,12H,1-9H2;1H
40576-21-4Relevant academic research and scientific papers
Design and synthesis of a hybrid series of potent and selective agonists of α7 nicotinic acetylcholine receptor
Nencini, Arianna,Castaldo, Cristiana,Comery, Thomas A.,Dunlop, John,Genesio, Eva,Ghiron, Chiara,Haydar, Simon,Maccari, Laura,Micco, Iolanda,Turlizzi, Elisa,Zanaletti, Riccardo,Zhang, Jean
, p. 401 - 418 (2014/04/17)
α7 nicotinic acetylcholine receptor agonists are promising therapeutic candidates for the treatment of cognitive impairment. As a follow up of our internal medicinal chemistry program we investigated a novel series of α7 nAChR agonists. Starting from molecular docking studies on two series of molecules recently developed in our laboratories, an alternative scaffold was designed attempting to combine the optimal features of these previously identified urea and pyrazole compounds. Based on our previous SAR knowledge and on predicted drug-like properties, a small library was synthesized in parallel manner, affording compounds with excellent α7 nAChR activity, selectivity and preliminary ADME profile.
